Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00138749 · ClinicalTrials.gov registry record · Phase 2
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 402
- Enrollment target
NCT00138749 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 402 participants.
The verdict
NCT00138749, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 402 participants
- Enrollment target
Study Summary
A study designed to assess the efficacy, toleration and safety of SS-RBX for the treatment of stress urinary incontinence.
Interventions
- DRUG SS-RBX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00138749
The ClinicalTrials.gov registry entry for NCT00138749 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SS-RBX is the first listed.
NCT00138749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00138749 about?
NCT00138749 is a clinical study titled "An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.". A study designed to assess the efficacy, toleration and safety of SS-RBX for the treatment of stress urinary incontinence.
What is the current status of trial NCT00138749?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 402 participants. The study started on 2004-11. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00138749?
The interventions under investigation include: SS-RBX (DRUG).
Who is sponsoring clinical trial NCT00138749?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.